Rumor Mill: UCB looks to sell peptides division in €100M deal

November 21, 2005 — 8:01pm ET

Gen-Probe bids $334 for Innogenetics
Solvay, Lundbeck shares tumble on news of psychosis drug delay
Solvay shelves obesity drug
Wyeth kills off Solvay pact
ALSO NOTED: BMS hands back drug rights; OncoMethylome in deal with GSK; Celgene shares take a bounce; and much more...
Researchers stage strike at J&J's Belgium ops
Galapagos inks massive RA deal with J&J
FDA, Gene Logic ink genomics deal
Ablynx plots IPO to advance nanobody pipeline
ALSO NOTED: Gates gives $280M to fight TB; Merck drug proves positive in Phase II;Merck KGaA exec eyes acquisitions;much more..

Tools

Email
Print
Contact Author

Belgium's UCB is reportedly planning to divest UCB-Bioproducts, its peptides unit, to Solvay for about €100 million. UCB has declined to comment on the report, which appeared in the financial daily de Tijd.

- read this report from AFX

Paid Research Reports

RNA therapy: the next big thing after monoclonal antibodies?
Biotech M&A Strategies: Deal assessments, trends and future prospects
The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
Sales Force Effectiveness

Most Popular Stories

Featured Jobs

Webinars

Popular Topics

Events

Rumor Mill: UCB looks to sell peptides division in €100M deal

Related Stories

Paid Research Reports

THE FIERCEMARKETS NETWORK